Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders)

Trial Profile

EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 28 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rosuvastatin (Primary)
  • Indications Hyperlipidaemia; Lipid metabolism disorders
  • Focus Therapeutic Use
  • Acronyms EMERALD

Most Recent Events

  • 23 May 2024 According to EISAI media release, announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Oncology Annual Meeting which is taking place virtually and inperson in Chicago, Illinois from May 31 to June 4.
  • 02 Aug 2023 Status changed from active, no longer recruiting to completed.
  • 30 Jun 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top